Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology

Daniel F.J. Ketelhuth, Esther Lutgens, Magnus Bäck, Christoph J. Binder, Jan Van den Bossche, Carolin Daniel, Ingrid E. Dumitriu, Imo Hoefer, Peter Libby, Luke O'Neill, Christian Weber, Paul C. Evans

Research output: Contribution to journalArticleAcademicpeer-review


Inflammation is an important driver of atherosclerosis, and the favourable outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial revealed the large potential of anti-inflammatory drugs for the treatment of cardiovascular disease, especially in patients with a pro-inflammatory constitution. However, the complex immune reactions driving inflammation in the vascular wall in response to an atherosclerotic microenvironment are still being unravelled. Novel insights into the cellular processes driving immunity and inflammation revealed that alterations in intracellular metabolic pathways are strong drivers of survival, growth, and function of immune cells. Therefore, this position paper presents a brief overview of the recent developments in the immunometabolism field, focusing on its role in atherosclerosis. We will also highlight the potential impact of immunometabolic markers and targets in clinical cardiovascular medicine.

Original languageEnglish
Pages (from-to)1385-1392
Number of pages8
JournalCardiovascular Research
Issue number9
Publication statusPublished - 1 Jan 2019

Cite this